Comparative Pharmacology
Head-to-head clinical analysis: ARANELLE versus TRI LO ESTARYLLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARANELLE versus TRI LO ESTARYLLA.
ARANELLE vs TRI-LO-ESTARYLLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and norgestimate. Suppresses gonadotropin secretion, primarily FSH and LH, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial lining, reducing implantation likelihood.
One tablet (norethindrone 1 mg and ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 days of placebo.
One tablet (20 mcg ethinyl estradiol/0.1 mg levonorgestrel) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Terminal half-life 12-14 hours; steady-state achieved within 2-3 days; clinical context supports once-daily dosing
Ethinyl estradiol: 19-24 hours (terminal); Norgestimate: active metabolite norelgestromin 28-38 hours; allows once-daily dosing.
Renal 50-60% as metabolites (sulfate and glucuronide conjugates), fecal 30-40%, biliary 10%
Renal: ~40% as metabolites; Fecal: ~30% as metabolites (including ethinyl estradiol conjugates); Biliary: ~20% (enterohepatic recirculation).
Category C
Category C
Oral Contraceptive
Oral Contraceptive